KODK : The sleeping giant.
Hello All. Here is my analysis that is not so far fetched.
Pros:
1. Partnership with microsoft.
2. Solid institutions bought in December 2020
3. Pharmaceutical Division pending
4. Low float count in available shares
5. Multiple failed breakouts but solid consolidation
6. Potential Loan coming from the Federal Government to kick start Pharmaceutical Division
CATALYST: Short interest is between 18% - 24%.
I am long with two short term targets. $17 & $20. Not to mention, calls are super bullish for this month all the way through April. Hang tight and be patient.
Pros:
1. Partnership with microsoft.
2. Solid institutions bought in December 2020
3. Pharmaceutical Division pending
4. Low float count in available shares
5. Multiple failed breakouts but solid consolidation
6. Potential Loan coming from the Federal Government to kick start Pharmaceutical Division
CATALYST: Short interest is between 18% - 24%.
I am long with two short term targets. $17 & $20. Not to mention, calls are super bullish for this month all the way through April. Hang tight and be patient.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.